Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine hydrolase-like protein (SERHL)
- Target
- SERHL
- Molecular classification
- Enzyme, Serine hydrolase, Alpha/beta-hydrolase fold protein
01
Overview
The **serine hydrolase-like protein (SERHL)**, encoded by the _SERHL_ gene, is an alpha/beta-hydrolase fold enzyme containing a conserved catalytic triad (often serine-histidine-aspartate) and a peroxisomal targeting signal[2]. It is upregulated in mouse skeletal muscle in response to passive mechanical stretch and may contribute to skeletal muscle hypertrophy by influencing peroxisomal function and/or metabolic signaling pathways. Like other serine hydrolases, SERHL catalyzes the hydrolytic cleavage of specific substrate bonds (esters, thioesters, amides). The precise endogenous substrates and physiological roles of SERHL are not completely characterized, but it is part of a large superfamily with diverse roles in metabolism, neurotransmission, inflammation, and diseases such as cancer and infection[2][1][4].
- Other names
- Serine hydrolase-like proteinSERHLSERHL2SHLHS126B42BK126B4.1dJ222E13.1kraken-like
02
Mechanism of action
Drugs targeting serine hydrolases generally act by covalently binding the active site serine, leading to enzyme inhibition (mechanism-based inactivators)
03
Biological functions
Hydrolytic cleavage of ester, thioester, and amide bondsPossible role in peroxisome functionPossible involvement in skeletal muscle growth in response to mechanical stimuli (stretch-induced hypertrophy)
04
Disease associations
Muscle hypertrophy and atrophy (potential involvement inferred from expression in response to muscle stretch)Other disease roles for the broader serine hydrolase family include cancer, inflammation, bacterial infection, and metabolic disorders, though a specific role for SERHL in these diseases is undetermined
05
Safety considerations
Safety issues for targeting SERHL specifically have not been describedInhibition of serine hydrolases broadly may risk off-target effects due to the abundance and variety of physiologically essential hydrolases
06
Interacting drugs
fluorophosphonates (FPs) (general serine hydrolase inhibitor)
1 more in the full profile.
07
Biomarkers
No specific biomarkers for patient selection or monitoring efficacy related to SERHL have been reportedActivity-based probes (e.g., FP-biotin) may be used experimentally to profile active serine hydrolases in tissues
Beyond the preview
Go deeper on Serine hydrolase-like protein (SERHL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serine hydrolase-like protein (SERHL).